Full Prescribing Information Contact Us Billing Information

COAGADEX SUPPORT FOR PATIENTS


Co-Pay Assistance

Eligible patients can receive up to $12,000 per year to cover the deductible, co-pay, and/or coinsurance for COAGADEX.

  • Please ask your provider to bill Medmonk for your co-pay assistance at the time of dispensing. This streamlined approach facilitates the process, ensuring prompt access to the copay assistance you need.
  • COAGADEX copay assistance can typically be used regardless of whether your healthcare provider is billing through your major medical plan or your pharmacy benefits.

Eligibility criteria for co-pay assistance
  • Valid for out-patient prescriptions only
  • The Coagadex Co-Pay Support Program is for patients who have a valid prescription for Coagadex regardless of financial need
Restrictions
  • Not valid for prescriptions eligible for reimbursement by any federal or state healthcare programs, such as Medicare, Medicaid, Medigap, Veterans Affairs, Department of Defense, Tricare, or any other federal or state-funded programs.
  • Patients whose insurance policy prohibits co-pay assistance are not eligible
  • Non-medication expenses, such as ancillary infusion supplies, are not eligible.

Reimbursement Support

Feel free to contact our Support Team at (888) 262-8040 and inquire about your insurance coverage. We're here to help you navigate your coverage and provide support where needed.


Clinical support

Please visit https://www.coagadex.com/support#resources for additional resources related to COAGADEX.



This program is subject to change or discontinuation by Kedrion Biopharma Inc. at any time, for any reason, and with or without prior notice.

Indications for COAGADEX

COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children (aged 12 years and above) with hereditary factor X deficiency for:

Limitation of use

Perioperative management of bleeding in major surgery in patients with severe hereditary factor X deficiency has not been studied.


Important Safety Information

COAGADEX is contraindicated in patients with known hypersensitivity to any of the components of the product.

Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately and contact their physician.

The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.

COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.

In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.

Please see full prescribing information for Coagadex.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Coagadex® is a registered trademark of Kedrion Biopharma Inc.
Coagadex is manufactured by Bio Products Laboratory U.S.A., Inc. and distributed by Kedrion Biopharma Inc.

US/X/0319/0016